問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kuang Tien General Hospital

Recruiting

List

29Cases

2023-10-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting5Sites

2025-06-01 - 2028-12-31

Phase II

Active
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease (COPD)

  • Test Drug

    Tablet

Participate Sites
10Sites

Recruiting10Sites

2021-05-20 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2024-03-01 - 2026-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2025-06-09 - 2029-11-26

Phase III

Not yet recruiting
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

  • Condition/Disease

    COPD with Type 2 inflammation

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2030-03-31

Phase III

Active
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer

  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    溶液用粉劑

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2025-11-30

Phase III

Completed
A Phase 3, Randomized, Observer‑blind, Active‑control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA‑1083 (SARS‑CoV‑2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age

  • Condition/Disease

    SARS‑CoV‑2 and Influenza

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2025-02-28 - 2032-06-30

Phase III

Active
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

  • Condition/Disease

    Early breast cancer that is lymph node–positive, estrogen receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative, with a high risk of recurrence.

  • Test Drug

    Elacestrant

Participate Sites
13Sites

Recruiting13Sites

2025-09-01 - 2030-06-30

Phase II

Active
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection Condensed Powder

Participate Sites
7Sites

Recruiting7Sites

2023-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB